Back to Search
Start Over
P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes
- Source :
- Breast, Vol 68, Iss , Pp S22-S23 (2023)
- Publication Year :
- 2023
- Publisher :
- Elsevier, 2023.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 15323080 and 09609776
- Volume :
- 68
- Issue :
- S22-S23
- Database :
- Directory of Open Access Journals
- Journal :
- Breast
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.75e8731e448a4b51922ee0d8e87c7fb3
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/S0960-9776(23)00136-4